This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.
In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.
In your application messsage, please share your background and what you can contribute to the group.
Company Overview and News
Xiaomi debut: Xiaomi chairman and CEO Lei Jun being greeted by Laura Cha, chairman of of Hong Kong Exchanges and Clearing Ltd (HKEX), as HKEX deputy chairman of listing committee John Ho (left) and Hong Kong Financial Secretary Paul Chan look on during the listing ceremony in Hong Kong. — Bloomberg
MLHK 0700 TRI
HONG KONG, June 29 ― China's Xiaomi Corp priced its Hong Kong initial public offering (IPO) at the bottom of an indicative range, raising US$4.72 billion (RM19.06 billion) in the world's biggest tech float in four years, people close to the transaction said today.
0941 BABA MLHK CHLKF CHL AAPL TRI QCOM
French insurer AXA plans to invest HK$200 million (US$25.48 million) on fintech development in Hong Kong this year to promote sales and reach younger consumers, according to its senior executive.
Brokers believe Hong Kong can support one blockbuster IPO from a unicorn such as Xiaomi at a time, but two or more to together may force them to decide how they allocate their lending
MLHK CWYCF CWYCY 0700
Miss your mother's home-made soup? There's an app where you can "rent a mum" to cook some for you. Need someone to courier a package at 2.30am? Looking for a pet dog for an Instagram project? There are apps for those too.
HKMA deputy Howard Lee warns homeowners to ‘be mindful’ of their mortgage repayment obligations as city’s monetary conditions become tighter
HONG KONG: The Hong Kong dollar fell to a fresh 33-year low on Thursday, hitting the weakest end of the monetary authority's targeted trading band amid persistent downside pressure as the interest rate gap between US and Hong Kong dollars widened further.
HONG KONG: Hong Kong flag carrier Cathay Pacific on Wednesday (Mar 14) booked the first back-to-back annual loss in its seven-decade history but said it was in the black for the second half and was upbeat about the next year.
ZNH MLHK 1055
Hong Kong flag carrier Cathay Pacific on Wednesday booked the first back-to-back annual loss in its seven-decade history but said it was in the black for the second half and was upbeat about the next year.
ZNH MLHK 1055
6h - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
7h - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...